drugset / Trial / NCT02251067
Phase 2 Study to Evaluate Safety & Efficacy of VPI-2690B in Diabetic Nephropathy Patients
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to determine whether VPI-2690B Injection is effective in the treatment of diabetic nephropathy.
Timeline
- Start
- 2014-09
- Primary completion
- 2017-03
- Completion
- 2017-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | VPI-2690B | Unknown | 6 mg | Subcutaneous |
| Comparator | VPI-2690B | Unknown | 18 mg | Subcutaneous |
| Comparator | VPI-2690B | Unknown | 48 mg | Subcutaneous |